Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
Jordan SloshowerPatrick D SkosnikHamideh Safi-AghdamSurbhi PathaniaShariful A SyedBrian PittmanDeepak Cyril D'SouzaPublished in: Journal of psychopharmacology (Oxford, England) (2023)
The results of this exploratory study highlight the complex interplay between expectancy, therapy effects, and drug/placebo effects in psychedelic-assisted psychotherapy studies. Nonetheless, the acute and persisting clinical improvements observed following psilocybin support further study of its potential in the treatment of major depression. Future studies should more explicitly mitigate and measure expectancy effects and assess the impact of repeated dosing and different forms of psychotherapeutic support.
Keyphrases
- major depressive disorder
- bipolar disorder
- clinical trial
- placebo controlled
- study protocol
- stem cells
- emergency department
- randomized controlled trial
- double blind
- mesenchymal stem cells
- intensive care unit
- drug induced
- bone marrow
- squamous cell carcinoma
- phase ii
- respiratory failure
- electronic health record
- cell therapy
- rectal cancer
- combination therapy
- replacement therapy